Molecular mechanisms, current management and next generation therapy in myeloma bone disease

References

• Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385:2197–2208.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2016;91:90–100.
   PubMed Web of Science ®Google Scholar
• Silbermann R, Roodman GD. Current controversies in the management of myeloma bone disease. J Cell Physiol. 2016;231:2374–2379.
   PubMed Web of Science ®Google Scholar
• Melton LJ, 3rd, Kyle RA, Achenbach SJ, et al. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20:487–493.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem. 2010;109:283–291.
   PubMed Web of Science ®Google Scholar
• Lecouvet F, Richard F, Vande Berg B, et al. Long-term effects of localized spinal radiation therapy on vertebral fractures and focal lesions appearance in patients with multiple myeloma. Br J Haematol. 1997;96:743–745.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485–1493.
   PubMed Web of Science ®Google Scholar
• Sonmez M, Akagun T, Topbas M, et al. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res. 2008;27:11.
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860–1867.
   PubMed Web of Science ®Google Scholar
• Wesseling-Perry K. The BRC canopy: an important player in bone remodeling. Am J Pathol. 2014;184:924–926.
   PubMed Web of Science ®Google Scholar
• Andersen TL, Soe K, Sondergaard TE, et al. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol. 2010;148:551–561.
   PubMed Web of Science ®Google Scholar
• Galson DL, Silbermann R, Roodman GD. Mechanisms of multiple myeloma bone disease. Bonekey Rep. 2012;1:135
   PubMedGoogle Scholar
• Walker RE, Lawson MA, Buckle CH, et al. Myeloma bone disease: pathogenesis, current treatments and future targets. Br Med Bull. 2014;111:117–138.
   PubMed Web of Science ®Google Scholar
• Cao H, Zhu K, Qiu L, et al. Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem. 2013;288:30399–30410.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–342.
   PubMed Web of Science ®Google Scholar
• Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102:1064–1069.
   PubMed Web of Science ®Google Scholar
• Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 2003;63:5438–5445.
   PubMed Web of Science ®Google Scholar
• Sezer O, Heider U, Jakob C, et al. Human bone marrow myeloma cells express RANKL. JCO. 2002;20:353–354.
   PubMed Web of Science ®Google Scholar
• Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98:3534–3540.
   PubMed Web of Science ®Google Scholar
• Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA. 2001;98:11581–11586.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Morandi F, et al. Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells. Haematologica. 2005;90:275–278.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Rizzoli V, et al. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment? Cancer Res. 2004;64:772–773. author reply 4-5.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Barlogie B. Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling. Immunol Rev. 2003;194:140–163.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Ferretti M, Bolzoni M, et al. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012;26:1391–1401.
   PubMed Web of Science ®Google Scholar
• Delgado-Calle J, Bellido T, Roodman GD. Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care. 2014;8:407–413.
   PubMed Web of Science ®Google Scholar
• Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood. 2000;96:1953–1960.
   PubMed Web of Science ®Google Scholar
• Hecht M, von Metzler I, Sack K, et al. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp Cell Res. 2008;314:1082–1093.
   PubMed Web of Science ®Google Scholar
• Colombo M, Thummler K, Mirandola L, et al. Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget. 2014;5:10393–10406.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Abe M, Hiasa M, et al. Myeloma cell–osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res. 2007;13:816–823.
   PubMed Web of Science ®Google Scholar
• Otjacques E, Binsfeld M, Noel A, et al. Biological aspects of angiogenesis in multiple myeloma. Int J Hematol. 2011;94:505–518.
   PubMed Web of Science ®Google Scholar
• Silvestris F, Ciavarella S, De Matteo M, et al. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both? Oncologist. 2009;14:264–275.
   PubMed Web of Science ®Google Scholar
• Binsfeld M, Muller J, Lamour V, et al. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget. 2016;7:37931–37943.
   PubMed Web of Science ®Google Scholar
• Sati HI, Apperley JF, Greaves M, et al. Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol. 1998;101:287–295.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96:671–675.
   PubMed Web of Science ®Google Scholar
• Silbermann R, Bolzoni M, Storti P, et al. Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia. 2014;28:951–954.
   PubMed Web of Science ®Google Scholar
• Westhrin M, Moen SH, Holien T, et al. Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. Haematologica. 2015;100:e511–e514.
   PubMed Web of Science ®Google Scholar
• Cafforio P, Savonarola A, Stucci S, et al. PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression. J Bone Miner Res. 2014;29:55–66.
   PubMed Web of Science ®Google Scholar
• Ersek A, Xu K, Antonopoulos A, et al. Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. J Clin Invest. 2015;125:2279–2292.
   PubMed Web of Science ®Google Scholar
• Liu H, Liu Z, Du J, et al. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci Transl Med. 2016;8:353ra113.
   PubMed Web of Science ®Google Scholar
• Kudo O, Sabokbar A, Pocock A, et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1–7.
   PubMed Web of Science ®Google Scholar
• Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treat Res. 2004;118:83–100.
   PubMedGoogle Scholar
• Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005;202:589–595.
   PubMed Web of Science ®Google Scholar
• Xu G, Liu K, Anderson J, et al. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood. 2012;119:4205–4214.
   PubMed Web of Science ®Google Scholar
• Derksen PW, de Gorter DJ, Meijer HP, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia. 2003;17:764–774.
   PubMed Web of Science ®Google Scholar
• Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A.2010;107:5124–5129.
   PubMed Web of Science ®Google Scholar
• Fu J, Li S, Feng R, et al. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J Clin Invest. 2016;126:1759–1772.
   PubMed Web of Science ®Google Scholar
• Han JH, Choi SJ, Kurihara N, et al. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001;97:3349–3353.
   PubMed Web of Science ®Google Scholar
• Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol. 2005;33:272–278.
   PubMed Web of Science ®Google Scholar
• Menu E, De Leenheer E, De Raeve H, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis. 2006;23:291–300.
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Szydlo R, et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 2003;123:106–109.
   PubMed Web of Science ®Google Scholar
• Pennisi A, Ling W, Li X, et al. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 2009;114:1803–1812.
   PubMed Web of Science ®Google Scholar
• Thomas GP, Baker SU, Eisman JA, et al. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol. 2001;170:451–460.
   PubMed Web of Science ®Google Scholar
• Raimondi L, De Luca A, Amodio N, et al. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget. 2015;6:13772–13789.
   PubMed Web of Science ®Google Scholar
• Noonan K, Marchionni L, Anderson J, et al. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 2010;116:3554–3563.
   PubMed Web of Science ®Google Scholar
• Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484–2491.
   PubMed Web of Science ®Google Scholar
• D’Souza S, Kurihara N, Shiozawa Y, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood. 2012;119:1888–1896.
   PubMed Web of Science ®Google Scholar
• Abe M, Kido S, Hiasa M, et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia. 2006;20:1313–1315.
   PubMed Web of Science ®Google Scholar
• Cackowski FC, Anderson JL, Patrene KD, et al. Osteoclasts are important for bone angiogenesis. Blood. 2010;115:140–149.
   PubMed Web of Science ®Google Scholar
• Dallas SL, Rosser JL, Mundy GR, et al. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem. 2002;277:21352–21360.
   PubMed Web of Science ®Google Scholar
• Reagan MR, Liaw L, Rosen CJ, et al. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone. 2015;75:161–169.
   PubMed Web of Science ®Google Scholar
• Nemani N, Santo L, Eda H, et al. Role of decorin in multiple myeloma (MM) bone marrow microenvironment. J Bone Miner Res. 2015;30:465–470.
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Wezeman MJ, Zangari M, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006;91:192–199.
   PubMed Web of Science ®Google Scholar
• Kassen D, Lath D, Lach A, et al. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. Br J Haematol. 2016;172:64–79.
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62–66.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005;106:2472–2483.
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, De Matteo M, et al. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. Clin Cancer Res. 2008;14:6081–6091.
   PubMed Web of Science ®Google Scholar
• D'Souza S, del Prete D, Jin S, et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood. 2011;118:6871–6880.
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483–2494.
   PubMed Web of Science ®Google Scholar
• Brunetti G, Oranger A, Mori G, et al. Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci. 2011;1237:19–23.
   PubMed Web of Science ®Google Scholar
• Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011;1:e27.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 2007;67:7665–7674.
   PubMed Web of Science ®Google Scholar
• Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106:3160–3165.
   PubMed Web of Science ®Google Scholar
• Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135:688–692.
   PubMed Web of Science ®Google Scholar
• Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood. 2008;112:196–207.
   PubMed Web of Science ®Google Scholar
• Eda H, Santo L, Wein MN, et al. Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease. J Bone Miner Res. 2016;31:1225–1234.
   PubMed Web of Science ®Google Scholar
• Li B, Shi M, Li J, et al. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev. 2007;16:921–930.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Abe M, Hiasa M, et al. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS ONE. 2010;5:e9870.
   PubMed Web of Science ®Google Scholar
• Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol. 2008;80:490–494.
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer. 2012;131:1466–1471.
   PubMed Web of Science ®Google Scholar
• Vallet S, Pozzi S, Patel K, et al. A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia. 2011;25:1174–1181.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kastritis E, Christoulas D, et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol. 2012;23:2681–2686.
   PubMed Web of Science ®Google Scholar
• Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 2007;109:3024–3030.
   PubMed Web of Science ®Google Scholar
• Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005;106:1407–1414.
   PubMed Web of Science ®Google Scholar
• Fowler JA, Lwin ST, Drake MT, et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood. 2011;118:5872–5882.
   PubMed Web of Science ®Google Scholar
• Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43:1670–1678.
   PubMed Web of Science ®Google Scholar
• Bruce NJ, McCloskey EV, Kanis JA, et al. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol. 1999;104:358–364.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, etet al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
   PubMed Web of Science ®Google Scholar
• Caers J, Fernandez de Larrea C, Leleu X, et al. The changing landscape of smoldering multiple myeloma: a European perspective. Oncologist. 2016;21:333–342.
   PubMed Web of Science ®Google Scholar
• Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. JCO. 2013;31:2347–2357.
   PubMed Web of Science ®Google Scholar
• Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol. 2013;162:50–61.
   PubMed Web of Science ®Google Scholar
• Pianko MJ, Terpos E, Roodman GD, et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clin Cancer Res. 2014;20:5888–5897.
   PubMed Web of Science ®Google Scholar
• Pecoraro V, Roli L, Germagnoli L, et al. The prognostic role of bone turnover markers in multiple myeloma patients: the impact of their assay. A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015;96:54–66.
   PubMed Web of Science ®Google Scholar
• Patel CG, Yee AJ, Scullen TA, et al. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014;20:3955–3961.
   PubMed Web of Science ®Google Scholar
• Dowling P, Hayes C, Ting KR, et al. Identification of proteins found to be significantly altered when comparing the serum proteome from multiple myeloma patients with varying degrees of bone disease. BMC Genomics. 2014;15:904.
   PubMed Web of Science ®Google Scholar
• Hao M, Zang M, Zhao L, et al. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget. 2016;7:19589–19600.
   PubMed Web of Science ®Google Scholar
• Papamerkouriou YM, Kenanidis E, Gamie Z, et al. Treatment of multiple myeloma bone disease: experimental and clinical data. Expert Opin Biol Ther. 2015;15:213–230.
   PubMed Web of Science ®Google Scholar
• Thompson K, Rogers MJ, Coxon FP, et al. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol. 2006;69:1624–1632.
   PubMed Web of Science ®Google Scholar
• Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209–257.
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Medicherla S, Coulton L, et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007;67:4572–4577.
   PubMed Web of Science ®Google Scholar
• Raje N, Vescio R, Montgomery CW, et al. Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study. Clin Cancer Res. 2016;22:1378–1384.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989–1999.
   PubMed Web of Science ®Google Scholar
• Chantry AD, Heath D, Mulivor AW, et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res. 2010;25:2633–2646.
   PubMed Web of Science ®Google Scholar
• Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003;18:482–492.
   PubMed Web of Science ®Google Scholar
• Shipman CM, Croucher PI, Russell RG, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58:5294–5297.
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384–392.
   PubMed Web of Science ®Google Scholar
• Terpos E, Roodman GD, Dimopoulos MA. Optimal use of bisphosphonates in patients with multiple myeloma. Blood. 2013;121:3325–3328.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kleber M, Engelhardt M, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254–1266.
   PubMed Web of Science ®Google Scholar
• Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84:632–637. quiz 8.
   PubMed Web of Science ®Google Scholar
• Zangari M, Suva LJ. The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone. 2016;86:131–138.
   PubMed Web of Science ®Google Scholar
• Pennisi A, Li X, Ling W, et al. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 2009;84:6–14.
   PubMed Web of Science ®Google Scholar
• Deleu S, Lemaire M, Arts J, et al. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res. 2009;69:5307–5311.
   PubMed Web of Science ®Google Scholar
• Hurchla M, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013;27:430–440.
   PubMed Web of Science ®Google Scholar
• Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin Cancer Res. 2014;20:1542–1554.
   PubMed Web of Science ®Google Scholar
• Oyajobi BO, Garrett IR, Gupta A, et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol. 2007;139:434–438.
   PubMed Web of Science ®Google Scholar
• Hongming H, Jian H. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res. 2009;33:115–122.
   PubMed Web of Science ®Google Scholar
• Zangari M, Terpos E, Zhan F, et al. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev. 2012;38:968–980.
   PubMed Web of Science ®Google Scholar
• Mohty M, Malard F, Mohty B, et al. The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer. 2014;120:618–623.
   PubMed Web of Science ®Google Scholar
• Munemasa S, Sakai A, Kuroda Y, et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol. 2008;33:129–136.
   PubMed Web of Science ®Google Scholar
• Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107:3098–3105.
   PubMed Web of Science ®Google Scholar
• Chang X, Zhu Y, Shi C, et al. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai). 2014;46:240–253.
   PubMed Web of Science ®Google Scholar
• Scullen T, Santo L, Vallet S, et al. Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia. 2013;27:1715–1721.
   PubMed Web of Science ®Google Scholar
• Bolomsky A, Schreder M, Meissner T, et al. Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. Exp Hematol. 2014;42:516–525.
   PubMed Web of Science ®Google Scholar
• Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97:887–892.
   PubMed Web of Science ®Google Scholar
• Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12:1221–1228.
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–1132.
   PubMed Web of Science ®Google Scholar
• Raje N, Vadhan-Raj S, Willenbacher W, et al. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer J. 2016;6:e378.
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371–379.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–1543.
   PubMed Web of Science ®Google Scholar
• Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014;165:814–823.
   PubMed Web of Science ®Google Scholar
• Iancu-Rubin C, Mosoyan G, Wang J, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013;41:155–166 e17.
   PubMed Web of Science ®Google Scholar
• Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311–319.
   PubMed Web of Science ®Google Scholar
• Dairaghi DJ, Oyajobi BO, Gupta A, et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 2012;120:1449–1457.
   PubMed Web of Science ®Google Scholar
• Neri P, Kumar S, Fulciniti MT, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007;13:5903–5909.
   PubMed Web of Science ®Google Scholar
• Schwarzer R, Nickel N, Godau J, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J. 2014;4:e217.
   PubMed Web of Science ®Google Scholar
• Menu E, Jernberg-Wiklund H, De Raeve H, et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer. 2007;121:1857–1861.
   PubMed Web of Science ®Google Scholar
• Lu A, Pallero MA, Lei W, et al. Inhibition of transforming growth factor-beta activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma. Am J Pathol. 2016;186:678–690.
   PubMed Web of Science ®Google Scholar
• Tai YT, Anderson KC. Bruton's tyrosine kinase: oncotarget in myeloma. Oncotarget. 2012;3:913–914.
   PubMed Web of Science ®Google Scholar
• Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120:1877–1887.
   PubMed Web of Science ®Google Scholar
• Heusschen R, Muller J, Binsfeld M, et al. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Oncotarget. 2016;7:30712–30729.
   PubMed Web of Science ®Google Scholar
• Garcia-Gomez A, Ocio EM, Crusoe E, et al. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS ONE. 2012;7:e34914.
   PubMed Web of Science ®Google Scholar
• Gan ZY, Fitter S, Vandyke K, et al. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. Eur J Haematol. 2015;94:343–354.
   PubMed Web of Science ®Google Scholar
• Martin SK, Gan ZY, Fitter S, et al. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leuk Res. 2015;39:380–387.
   PubMed Web of Science ®Google Scholar
• Teramachi J, Silbermann R, Yang P, et al. Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo. Leukemia. 2016;30:390–398.
   PubMed Web of Science ®Google Scholar
• He J, Liu Z, Zheng Y, et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 2012;72:6393–6402.
   PubMed Web of Science ®Google Scholar
• Venkateshaiah SU, Khan S, Ling W, et al. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013;41:547–557 e2.
   PubMed Web of Science ®Google Scholar
• Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011;12:225–235.
   PubMed Web of Science ®Google Scholar
• McDonald RJ, Trout AT, Gray LA, et al. Vertebroplasty in multiple myeloma: outcomes in a large patient series. AJNR Am J Neuroradiol. 2008;29:642–648.
   PubMed Web of Science ®Google Scholar
• Talamo G, Dimaio C, Abbi KK, et al. Current role of radiation therapy for multiple myeloma. Front Oncol. 2015;5:40.
   PubMed Web of Science ®Google Scholar
• Price P, Hoskin PJ, Easton D, et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986;6:247–255.
   PubMed Web of Science ®Google Scholar
• Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97:798–804.
   PubMedGoogle Scholar
• Heusschen R, Muller J, Withofs N, et al. Multiple myeloma bone disease: from mechanisms to next generation therapy. Belg J Hematol. 2017;8:66–74.
   Google Scholar
• Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71–73.
   PubMed Web of Science ®Google Scholar
• Heider U, Kaiser M, Müller C, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006;77:233–238.
   PubMed Web of Science ®Google Scholar
• Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia. 2005;19:1969–1976.
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Kokkoris P, et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol. 2010;21:1561–1562.
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Kastritis E, et al. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. Am J Hematol. 2014;89:34–40.
   PubMed Web of Science ®Google Scholar
• Delforge M, Terpos E, Richardson PG, et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011;86:372–384.
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Cellini C, et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol. 2006;76:399–404.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–1571.
   PubMed Web of Science ®Google Scholar
• Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009;84:650–656.
   PubMed Web of Science ®Google Scholar